AlbertE, it's very simple; the chemotherapy that all the subjects in the trial/s were receiving did that. The resection rates from the trial subjects with the Oncosil device implant must not have been found to be statistically any higher than subjects who only received chemotherapy (i.e., those not on the trial).
It's time to put the pom-poms down mate.
I think the market should be asking who the internal medical and regulatory advice came from. It doesn't seem to have steered them well.
Ann: CE Marking Update, page-42
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $69.42K | 8.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 28673846 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 7597003 | 11 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |
